[2] Vinod P. Balachandran, Luis A. et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 2022 40:16_suppl, 2516-2516.[3] Burris HA, Patel MR, Cho DC, et al. A phase I ...
RNA肿瘤疫苗属于核酸疫苗，它通过寻找可以编码肿瘤细胞抗原蛋白的氨基酸序列的基因（DNA 或RNA ），RNA肿瘤疫苗一般是使用翻译蛋白质的模板信使RNA（mRNA），以此为基础完成制备并注射入体内，通过人体细胞的蛋白质合成系统合成出特异性抗原蛋白，作为“靶标”，诱导机体产生对“靶标”的免疫应答，进而针对性攻击肿瘤细胞。
[2] Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022 Oct;23(10):e450-e458. doi: 10.1016/S1470-2045(22)00372-2.[3] Thiago Carvalho. Personalized anti-cancer vaccine combining mRNA and immunotherapy...
在肿瘤疫苗(cancer vaccine)中,CD8+ T细胞的诱导特别有意思,其目标是杀死靶向的肿瘤细胞,也可用于抗病毒疫苗(anti-viral vaccine)以消除受感染的细胞。然而,尽管核酸疫苗具有潜在优势,但它们是否会在人体中被良好地耐受并刺激足够强大的免疫反应,能否作为临床疫苗开发的一条可行性途径,这一点尚不清楚。 最初,DNA疫苗...
Their phasel trial involved sequential administration of anti-PD-L1 antibody (atezolizumab), an individualized mRNA neoantigen vaccine containing up to 20 neoantigens in nanoparticles (autogene cevumeran) and a four-drug chemotherapy regimen (mFOLFIRINOX) to patients with surgically resectable PDAC. ...
Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers ...
2022年10月,哥本哈根大学Inge Marie Svane作为通讯作者在Lancet Oncol期刊(IF: 54.433)发表综述文章《Clinical advances and ongoing trials on mRNA vaccines for cancer treatment》,基于mRNA递送系统分类,对当前mRNA肿瘤治疗性疫苗的临床研究现状进行了深度回顾。
[2] Vinod P. Balachandran, Luis A. et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 2022 40:16_suppl, 2516-2516. [3] Burris HA, Patel MR, Cho DC, et al. A phase I multic...
[2] Vinod P. Balachandran, Luis A. et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 2022 40:16_suppl, 2516-2516. [3] Burris HA, Patel MR, Cho DC, et al. A phase ...
elicit a robust immune response capable of controlling or eradicating the tumor. The versatility of mRNA technology allows for the simultaneous targeting of multiple antigens, which could improve the effectiveness of the vaccine by addressing tumor heterogeneity—a ...